Leitate Medical

Linatech was founded in the United States in the 20th century, deeply engaged in tumor radiotherapy for thirty years. Through continuous technological innovation, it provides precise treatment solutions for tumor patients. The company has obtained more than 170 intellectual property rights (87 invention patents) and holds 13 medical device registration certificates. The star product, VenusX medical electron linear accelerator, owns intellectual property rights in both China and the United States, with core technology independently controllable. The innovative product, VenusPlus, newly launched, enables more precise stereotactic radiotherapy. The breakthrough product, SuperX robotic accelerator, has been approved as a key R&D project under the 14th Five-Year Plan by the Ministry of Industry and Information Technology.
Leitate Medical takes the development of new quality productive forces as its core driving force, based on the dual-wheel drive of technological innovation and industrial upgrading, relying on the construction of "dual centers" in Beijing and Suzhou as a strong engine, creating a new development pattern of "dual wings flying together", and fully promoting the efficient linkage and deep integration of domestic and international "dual circulation". With Beijing as the headquarters base, it focuses on the shaping and promotion of the well-known brand of "produced in Beijing, used in Beijing", fully leveraging Beijing's comprehensive advantages in policy support, scientific research resources, innovative talents, and clinical transformation, gradually achieving a leapfrog development strategy from "produced in Beijing, used nationwide" to "produced in Beijing, used globally", and promoting China's independently innovative medical equipment to the world stage.